Biotech · Private company · Santa Ana, CA, US
NKGen Biotech, Inc.
SEC CIK 0001845459
Track this companyFree. Adds NKGen Biotech, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- AFM24Phase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- SNK01Phase 2 · Moderate Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SNK01Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SNK01Phase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- AvelumabPhase 1 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- SNK01Phase 1 · Refractory CancerClinicalTrials.gov · fetched Nov 12, 2026
- SNK02Phase 1 · Pathologically Confirmed Cancer Refractory to Conventional TherapyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Open-Label Extension Protocol to SNK01-AD01 StudyPHASE2 · RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT07228078 · fetched Nov 12, 2026
- Clinical Study of SNK01 in Participants With Moderate Alzheimer's DiseasePHASE1_PHASE2 · RECRUITING · started Nov 21, 2023ClinicalTrials.gov NCT06189963 · fetched Nov 12, 2026
- Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional TherapyPHASE1 · COMPLETED · started Aug 23, 2023ClinicalTrials.gov NCT05990920 · fetched Nov 12, 2026
- Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersPHASE1_PHASE2 · TERMINATED · started Nov 3, 2021ClinicalTrials.gov NCT05099549 · fetched Nov 12, 2026
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional TherapyPHASE1 · COMPLETED · started Jul 15, 2019ClinicalTrials.gov NCT03941262 · fetched Nov 12, 2026
SEC filings12
- 8-K · CURRENT REPORTSEC EDGAR · filed Sep 2, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jul 17, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 2, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed May 21, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Apr 21, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Feb 5, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jan 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jan 20, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jan 16, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jan 9, 2026 · fetched Nov 12, 2026